Cytokine-mediated blood brain barrier disruption as a conduit for cancer/chemotherapy-associated neurotoxicity and cognitive dysfunction

Files

hdl_104783.pdf (356.75 KB)
  (Accepted version)

Date

2016

Authors

Wardill, H.
Mander, K.
Van Sebille, Y.
Gibson, R.
Logan, R.
Bowen, J.
Sonis, S.

Editors

Advisors

Journal Title

Journal ISSN

Volume Title

Type:

Journal article

Citation

International Journal of Cancer, 2016; 139(12):2635-2645

Statement of Responsibility

Hannah R. Wardill, Kimberley A. Mander, Ysabella Z.A. Van Sebille, Rachel J. Gibson, Richard M. Logan, Joanne M. Bowen, and Stephen T. Sonis

Conference Name

Abstract

Neurotoxicity is a common side effect of chemotherapy treatment, with unclear molecular mechanisms. Clinical studies suggest that the most frequent neurotoxic adverse events affect memory and learning, attention, concentration, processing speeds and executive function. Emerging preclinical research points toward direct cellular toxicity and induction of neuroinflammation as key drivers of neurotoxicity and subsequent cognitive impairment. Emerging data now show detectable levels of some chemotherapeutic agents within the CNS, indicating potential disruption of blood brain barrier integrity or transport mechanisms. Blood brain barrier disruption is a key aspect of many neurocognitive disorders, particularly those characterized by a proinflammatory state. Importantly, many proinflammatory mediators able to modulate the blood brain barrier are generated by tissues and organs that are targets for chemotherapy-associated toxicities. This review therefore aims to explore the hypothesis that peripherally derived inflammatory cytokines disrupt blood brain barrier permeability, thereby increasing direct access of chemotherapeutic agents into the CNS to facilitate neuroinflammation and central neurotoxicity.

School/Discipline

Dissertation Note

Provenance

Description

Access Status

Rights

© 2016 UICC

License

Grant ID

Call number

Persistent link to this record